Ignite Creation Date:
2025-12-24 @ 6:47 PM
Ignite Modification Date:
2025-12-31 @ 9:04 AM
Study NCT ID:
NCT00996957
Status:
COMPLETED
Last Update Posted:
2013-03-18
First Post:
2009-10-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma
Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-10
Start Date Type:
None
Primary Completion Date:
2012-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-10
Completion Date Type:
ACTUAL
First Submit Date:
2009-10-09
First Submit QC Date:
None
Study First Post Date:
2009-10-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2013-03-14
Last Update Post Date:
2013-03-18
Last Update Post Date Type:
ESTIMATED